ASCO 2024 study: Early olaparib treatment may improve therapy duration and survival, using ConcertAI data

ConcertAI, a prominent player in oncology predictive and generative AI SaaS and Real-World Data (RWD) solutions for clinical research, has revealed findings from a study that will be showcased at the ASCO Annual Meeting 2024. This study, conducted in collaboration with pharmaceutical giants Merck & Co., Inc., and AstraZeneca, indicates that early treatment with olaparib monotherapy may enhance therapy duration and overall survival for patients with metastatic castration-resistant prostate cancer (mCRPC).

The research leveraged ConcertAI's extensive oncology dataset to analyze real-world data. It was observed that many patients with mCRPC who have homologous recombination repair gene mutation (HRRm) are administered multiple lines of therapy before receiving olaparib, even when novel hormonal agents (NHA) are introduced prior to mCRPC development. The study focused on HRRm+ patients aged 21 and above, with a confirmed mCRPC diagnosis, who were treated with olaparib monotherapy after May 19, 2020, and before receiving abiraterone or enzalutamide. Data were extracted from electronic medical records within the ConcertAI Oncology Dataset, encompassing PC diagnoses between 1990 and 2023. The study summarized the frequency of patients transitioning from metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic CRPC (nmCRPC) to mCRPC, as well as treatment patterns before mCRPC.

Jeff Elton, PhD, CEO of ConcertAI, highlighted the significance of the study, stating, "This research accentuates the value of real-world data in guiding specific treatment decisions and enhancing patient outcomes. By scrutinizing our extensive dataset of de-identified patient records, we demonstrated that early administration of olaparib can substantially extend therapy duration and improve overall survival for mCRPC patients. This aligns with our mission to convert data from electronic health records into actionable insights that benefit patient care directly."

The findings will be presented during a poster session at the ASCO Annual Meeting 2024 on Sunday, June 2, from 9:00 am to 12:00 pm. Attendees can visit poster #460 for more details. Additionally, ConcertAI will have a booth, number 12045, open throughout the exhibit hall hours.

ConcertAI stands as a leading entity in Predictive and Generative AI SaaS and Real-World Data research solutions within healthcare and life sciences. The company's mission is to expedite insights and outcomes for patients by utilizing research-ready data, AI technology, and scientific expertise in collaboration with top biomedical innovators, healthcare providers, and medical societies. ConcertAI's solutions are implemented across 2,000 clinical providers globally and 45 premier biopharmaceutical firms. Headquartered in Cambridge, MA, ConcertAI also has offices in Frankfurt, London, Philadelphia, Raleigh-Durham, and Tokyo.